Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer

Table 3 Variables associated with ET initiation by the 12-month interview and ET continuation for at least 12 months after initiation in the pooled sample

	ET initiation^a	ET continuation^b
Independent variables	aOR (95% CI) (n = 533)	aOR (95% CI) (n = 410)
Race
White	Ref.	Ref
Black/Other^c	0.66 (0.38-1.13)	0.85 (0.39-1.85)
Age, years	1.01 (0.98-1.03)	0.97 (0.93-1.00)
Insurance status
Private	Ref.	Ref
Public only or other^d	0.94 (0.52-1.71)	1.12 (0.47-2.69)
Chemotherapy
No	Ref.	Ref
Yes	3.47 (1.77-6.78)^*	1.23 (0.57-2.66)
Radiation Therapy
No	Ref.	Ref
Yes	3.94 (2.47-6.31)^*	1.42 (0.70-2.89)
Diabetes
No	Ref.	Ref
Yes	0.50 (0.27-0.91)^*	0.84 (0.34-2.04)
Obesity
No (BMI < 30 kg/m²)	Ref.	Ref
Yes (BMI ≥ 30 kg/m²)	1.12 (0.67-1.88)	1.03 (0.52-2.03)
Elevated depressed mood
No (CESD < 16)	Ref.	Ref
Yes (CESD ≥16)	0.79 (0.41-1.50)	0.46 (0.19-1.11)
Menopausal-symptom severity	1.35 (0.99-1.85)	0.67 (0.45-0.98)^*
Change in menopausal-symptom severity mean scores^e	–	1.04 (0.66-1.62)

ET endocrine therapy, BMI body mass index, aOR adjusted odds ratio, CI confidence interval, CESD Center for Epidemiologic Studies Depression scale
^a Using diabetes, obesity, elevated depressed mood, and menopausal symptom data from the interview prior to first report of ET initiation. For non-initiators and patients who first reported ever taking ET at baseline, the baseline measures of these four variables were used
^b Using diabetes, obesity, elevated depressed mood, and menopausal symptom data from the interview when ET initiation was first reported
^c This category includes 216 black, two Asian Indian/Pakistani, two Asian/Pacific Islander, and two unspecified race in the ET initiation model, with one fewer Asian/Pacific Islander in the ET continuation model
^d Other insurance status includes no insurance or self-pay
^e Change in menopausal-symptom severity mean scores from patient’s first reported use of ET to 12-18 month follow-up of ET continuation among patients who had used ET within 12 months of definitive surgery
^* P < 0.05

ISSN: 1471-2407